235 related articles for article (PubMed ID: 16434487)
1. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
Palladini G; Lavatelli F; Russo P; Perlini S; Perfetti V; Bosoni T; Obici L; Bradwell AR; D'Eril GM; Fogari R; Moratti R; Merlini G
Blood; 2006 May; 107(10):3854-8. PubMed ID: 16434487
[TBL] [Abstract][Full Text] [Related]
2. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
5. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
7. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
9. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G; Lousada I; Ando Y; Dispenzieri A; Gertz MA; Grogan M; Maurer MS; Sanchorawala V; Wechalekar A; Palladini G; Comenzo RL
Leukemia; 2016 Oct; 30(10):1979-1986. PubMed ID: 27416985
[TBL] [Abstract][Full Text] [Related]
10. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
[TBL] [Abstract][Full Text] [Related]
11. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
[TBL] [Abstract][Full Text] [Related]
13. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
[TBL] [Abstract][Full Text] [Related]
14. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery.
Schouten O; Hoeks SE; Goei D; Bax JJ; Verhagen HJ; Poldermans D
J Vasc Surg; 2009 Feb; 49(2):435-41; discussion 441-2. PubMed ID: 19028043
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
[TBL] [Abstract][Full Text] [Related]
16. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
[TBL] [Abstract][Full Text] [Related]
17. The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
Goei D; Flu WJ; Hoeks SE; Galal W; Dunkelgrun M; Boersma E; Kuijper R; van Kuijk JP; Winkel TA; Schouten O; Bax JJ; Poldermans D
Anesth Analg; 2009 Nov; 109(5):1403-8. PubMed ID: 19843778
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
[TBL] [Abstract][Full Text] [Related]
19. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
20. NT-proBNP Predicts Cardiovascular Death in the General Population Independent of Left Ventricular Mass and Function: Insights from a Large Population-Based Study with Long-Term Follow-Up.
Dietl A; Stark K; Zimmermann ME; Meisinger C; Schunkert H; Birner C; Maier LS; Peters A; Heid IM; Luchner A
PLoS One; 2016; 11(10):e0164060. PubMed ID: 27711172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
